Bought it a few months ago at 24 was over 30 and closed today at 27.5.....mentioned it here a while back.
The stock....CEGE (cell genesis)
The story....
1. Assets...owns 12% of Abgenix ABGX stock (10,000,000)shares at 88 today worth 880,000,000 and has 232,000,000 in cash ....thats 1.1B WOW!...only 33m shares outstanding....you do the math.
2.Science- Has promising pre clinical trials planned for gene therapies for hemophelia,,parkinsons,pancreatic cancer, and cardiovascular disease....this year
Has a multi-center Phase 1 and phase 2 trial underway with promising data showing for lung cancer vaccine GVAX (R)
Has 2 multi center phase2 human clinical trials underway for prostate.
Has a licensing program for its gene activation technology and has 235 issued patents with 330 pending 80 related to gene activation tech. That seems like a lot of free science since the company has cash and stock worth more than the share price.
I know of NO other Bio-tech selling even close to Book value or in a better position to acquire assets and still fully fund its research. Any Thoughts...I know I.E. thought it undervalued a few months ago
The stock....CEGE (cell genesis)
The story....
1. Assets...owns 12% of Abgenix ABGX stock (10,000,000)shares at 88 today worth 880,000,000 and has 232,000,000 in cash ....thats 1.1B WOW!...only 33m shares outstanding....you do the math.
2.Science- Has promising pre clinical trials planned for gene therapies for hemophelia,,parkinsons,pancreatic cancer, and cardiovascular disease....this year
Has a multi-center Phase 1 and phase 2 trial underway with promising data showing for lung cancer vaccine GVAX (R)
Has 2 multi center phase2 human clinical trials underway for prostate.
Has a licensing program for its gene activation technology and has 235 issued patents with 330 pending 80 related to gene activation tech. That seems like a lot of free science since the company has cash and stock worth more than the share price.
I know of NO other Bio-tech selling even close to Book value or in a better position to acquire assets and still fully fund its research. Any Thoughts...I know I.E. thought it undervalued a few months ago